Trial Report Plasma cell targeting with the anti-CD38 antibody daratumumab in ME/CFS -a clinical pilot study, 2025, Fluge et al

Without giving too much info, I'm all in on boosting Nk cells.... we shall what Anktiva does. I will definitely do a better job reporting than Julie for sure.

My ALC is 1000, basically borderline low and in line with some chemo patients. My NK is 6% of total lymphocytes and 62/ul. Very very low. So it needs something.

Not sure if the 5 covid infections I had in the past 2 years prior to ME had something to do with it..
 
Back
Top Bottom